Thyroid hormone status regulates the expression of secretory phospholipases

Thyroid hormone (13) stimulates various metabolic pathways and the hepatic actions of 13 are mediated primarily through the thyroid hormone receptor beta (TR beta). Hypothyroidism has been linked with low grade inflammation, elevated risk of hepatic steatosis and atherosclerosis. Secretory phospholipases (sPLA2) are associated with inflammation, hyperlipidemia and atherosclerosis. Due to potential linkage between thyroid hormone and sPLA2, we investigated the effect of thyroid hormone status on the regulation of secretory phospholipases in mice, rats and human liver. T3 suppressed the expression of the sPLA2 group ha (PLA2g2a) gene in the liver of BALB/c mice and C57BL/6 transgenic mice expressing the human PLA2g2a. PLA2g2a was elevated with hypothyroidism and high fat diets which may contribute to the low grade inflammation associated with hypothyroidism and diet induced obesity. We also examined the effects of the TR beta agonist eprotirome on hepatic gene regulation. We observed that eprotirome inhibited the expression of selected sPL42 genes and furthermore the cytokine mediated induction PLA2g2a was suppressed. In addition, eprotirome induced genes involved in fatty acid oxidation and cholesterol clearance while inhibiting lipogenic genes. Our results indicate that in vivo thyroid hormone status regulates the abundance of sPLA2 and the inhibition of PLA2g2a by 13 is conserved across species. By regulating sPLA2 genes, 13 may impact processes associated with atherosclerosis and inflammation and TR beta agonists may ameliorate inflammation and hyperlipidemia. (C) 2014 Elsevier Inc. All rights reserved.